-
Haemonetics Corporation recently reported its second quarter results, revealing a year-over-year sales decline to US$327.32 million but an increase in net income to US$38.68 million.
-
Despite revenue pressures, profit growth and ongoing confidence from analysts in the company’s differentiated products and R&D investment remain key points of interest.
-
We’ll examine how the stronger profitability amid competitive pressures impacts Haemonetics’ overall investment narrative and outlook.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
To be a shareholder in Haemonetics, you need to trust in the company’s ability to maintain earnings growth through new product innovation and margin expansion, even as revenue faces short-term softness. The recent Q2 results, showing higher net income despite falling sales, do not materially change the biggest catalyst, which remains increased adoption of NexSys and TEG systems; however, the greatest near-term risk continues to be competitive pressures in the vascular closure segment.
Among recent developments, the Q2 results reinforce the importance of product mix and operational execution. While sales were slightly down, increased profitability highlights management’s focus on margin resilience, which supports confidence in the catalyst of expanding high-margin product adoption.
Yet, in contrast, investors should stay alert to the ongoing risk around prolonged competition in vascular closure and the implications if…
Read the full narrative on Haemonetics (it’s free!)
Haemonetics’ outlook anticipates $1.5 billion in revenue and $257.9 million in earnings by 2028. This scenario assumes 2.6% annual revenue growth and a $94.6 million increase in earnings from the current $163.3 million.
Uncover how Haemonetics’ forecasts yield a $76.27 fair value, a 12% upside to its current price.
The Simply Wall St Community submitted three fair value estimates ranging widely from US$70.70 to US$99.06 per share. Given the broad spectrum of opinions, consider how ongoing competitive risks in core segments could influence future profitability and make sure to weigh multiple viewpoints when forming your outlook.
Explore 3 other fair value estimates on Haemonetics – why the stock might be worth as much as 45% more than the current price!
link